A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

754 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-29

Study Completion Date

2023-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

bIosimilar of aDalimumab, an European evAluation

NCT05190484

Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis +2 more

UNKNOWN

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis

NCT03110094

Rheumatoid Arthritis

COMPLETED NA

Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

NCT03561649

Spondylitis, Ankylosing

COMPLETED NA

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

NCT03662919

Arthritis, Rheumatoid Spondylitis, Ankylosing Arthritis, Psoriatic +2 more

COMPLETED

Predictors of the Response to Adalimumab in Rheumatoid Arthritis

NCT00234234

Rheumatoid Arthritis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease Ulcerative Colitis Psoriasis Ankylosing Spondylitis Rheumatoid Arthritis Psoriatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients at least 18 years old who agree to participate in the study and do not object to the use of their health data
* A disorder treated with anti-TNF therapy
* Whose physician made the decision to initiate adalimumab treatment prior to the study

Exclusion Criteria

* Patients participating in an interventional therapeutic trial at the time of inclusion
* Patients who are unwilling or unable to fulfil follow-up requirements (patients who cannot be reached by phone or complete the self-administered questionnaire or not fluent in French

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No